IDEC-131: IDPH said it has placed on hold all ongoing trials of IDEC-131. The company said that it has identified a risk of thromboembolism and that it needs to

Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif.
Product: IDEC-131
Business: Autoimmune/Inflammation
Therapeutic category:

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE